[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-371146-105":59,"doc-detail-371146-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","long-term-cardiac-morbidity-in-adolescent-and-young-adult-survivors-of-classical-hodgkin-lymphoma-the-british-columbia-experience","Long-term cardiac morbidity in adolescent and young adult survivors of classical Hodgkin lymphoma - the British Columbia experience","","Adolescents and young adults (AYA) with classical Hodgkin lymphoma (cHL) often survive long term, yet cardiovascular late effects from treatment can increase long-term morbidity and mortality. Using population-level administrative data, investigators estimated cardiovascular disease rates in 2-year AYA survivors aged 16–39 treated with ABVD or equivalent chemotherapy, with or without radiotherapy. After median 17 years follow-up, CVD risk was 2.9-fold higher versus controls, with heart failure and ischemic heart disease risks and cumulative incidences elevated.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/long-term-cardiac-morbidity-in-adolescent-and-young-adult-survivors-of-classical-hodgkin-lymphoma-the-british-columbia-experience/371146/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/long-term-cardiac-morbidity-in-adolescent-and-young-adult-survivors-of-classical-hodgkin-lymphoma-the-british-columbia-experience/371146.png","ImageObject",300,407,{"name":92,"@type":93},"moss~","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What late cardiovascular outcomes were assessed in AYA classical Hodgkin lymphoma survivors?","Question",{"text":113,"@type":114},"The study evaluated overall cardiovascular disease, including heart failure and ischemic heart disease, comparing 2-year survivors with controls over long follow-up.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How did heart failure and ischemic heart disease risks differ between survivors and controls?",{"text":118,"@type":114},"Risk of cardiovascular disease was 2.9-fold higher overall; heart failure risk was 5.2-fold higher and ischemic heart disease risk was 2.4-fold higher relative to controls, with higher cumulative incidences at 20 years.",{"name":120,"@type":111,"acceptedAnswer":121},"Which treatment exposures were linked to higher heart failure versus ischemic heart disease risk?",{"text":122,"@type":114},"Heart failure risk was associated with anthracycline-containing chemotherapy regimens alone or with combined modality therapy, while higher ischemic heart disease risk was identified only in those treated with radiotherapy.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},371146,1790344702,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},962090895452,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","ARTICLE-Hodgkin Lymphoma  \nLong-term cardiac morbidity in adolescent and young adult survivors of classical Hodgkin lymphoma: the British Columbia experience  \nKristin C. Marr,1 Terry Tang,2 Jonathan Simkin,2 Jewon Kim,3 Andrea C. Lo,4 Diego Villa,5 Alina S. Gerrie,5 Greg Hapgood,5° David W. Scott,5 Laurie H. Sehn,5 Ryan R Woods2,6 and Kerry J. Savage5  \n1 Division of Pediatric Hematology/Oncology, BC Children’s Hospital, University of British Columbia, Vancouver, British Columbia; 2 Department of Population Health Sciences, BC Cancer Research Centre, Data and Analytics, BC Cancer, Vancouver, British Columbia;  \n3 Department of Population Health Sciences, BC Cancer Research Centre, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario; 4 Division of Radiation Oncology, BC Cancer, University of British Columbia, Vancouver, British Columbia; 5 BC Cancer’s Centre for Lymphoid Cancer and Department of Medicine, University of British Columbia, Vancouver, British Columbia and 6 Department of Population Health Sciences, BC Cancer Research Centre, School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada  \n°Current address: Department of Haematology, Princess Alexandra Hospital and School of Medicine, University of Queensland, Brisbane, Queensland, Australia  \nAbstract  \nCorrespondence: K.C. Marr  \n[Kristin.marr@cw.bc.ca](Kristin.marr@cw.bc.ca)  \nK.J. Savage  \nksavage@bccancer.bc.ca  \nReceived: May 21, 2025.  \nAccepted: October 1, 2025.  \nEarly view: October 9, 2025.  \n[https://doi.org/10.3324/haematol.2025.288058](https://doi.org/10.3324/haematol.2025.288058)  \n©2026 Ferrata Storti Foundation  \nPublished under a CC BY-NC license   \nAdolescents and young adults (AYA) with classical Hodgkin lymphoma (cHL) have excellent survival outcomes. However, the late effects of treatment, including cardiovascular disease (CVD), can impact long-term disease-free morbidity and mortality. Using population-level administrative data, we evaluated rates of CVD in 2-year AYA survivors of cHL, aged 16-39 years, treated with ABVD or equivalent chemotherapy, with or without radiotherapy (RT) . With a median follow up of 17 years (range 2.3-29 years), risk of CVD was 2.9-fold higher relative to controls, with a 5.2-fold risk of heart failure (HF) and 2.4-fold risk of ischemic heart disease (IHD) . Risk of HF was associated with anthracycline-containing chemotherapy regimens alone or with combined modality therapy; whereas higher IHD risk was identified only in those treated with RT. At 20 years after the most recent cHL diagnosis or relapse, the cumulative incidence of HF was 4.3% in cases versus 0.8% in controls, and for IHD was 8.3% in cases versus 2.8% in controls. Treatment after 2005 using a PET scan guided approach reduced the overall use of RT (56.0% before 2005 vs. 14.9% 2005 and after), and was associated with a lower 15-year cumulative incidence of IHD (before 2005: 3.4%[95%CI: 1.8-5.1%]; 2005 and after: 0.7%[95%CI: 0-1.7%]) with the latter era comparable to controls; (1.6%[95%CI: 1.3-1.9%]) . cHL survivors had increased 20-year cumulative mortality above that of age-matched controls (5.0% vs. 2.0%) . These results can inform surveillance strategies, screening guidelines, and recommendations for risk factor modification for AYA cHL survivors.  \nIntroduction  \nClassical Hodgkin lymphoma (cHL) is one of the most commonly diagnosed malignancies in adolescents and young adults (AYA) with a peak incidence between the age of 15 and 34 years.1,2 ABVD (doxorubicin, bleomycin,  \nvinblastine, dacarbazine) was first introduced 50 years ago3 and has been a standard therapy since that time. With 5-year overall survival over 90%,4,5 there is a significant population of long-term survivors. The late effects of chemotherapy and radiation therapy (RT) used in cHL are well documented in children and adolescents with  \nHaematologica | 110 September 2025  \nARTICLE-HF and IHD in AYA survivors of c","cbCaiceSsMCxLWTL","https://ap.wps.com/l/cbCaiceSsMCxLWTL","pdf",981286,11,"English","# Abstract\n## Introduction\n### Background and rationale for studying late cardiovascular effects in AYA cHL survivors","[{\"question\":\"What late cardiovascular outcomes were assessed in AYA classical Hodgkin lymphoma survivors?\",\"answer\":\"The study evaluated overall cardiovascular disease, including heart failure and ischemic heart disease, comparing 2-year survivors with controls over long follow-up.\"},{\"question\":\"How did heart failure and ischemic heart disease risks differ between survivors and controls?\",\"answer\":\"Risk of cardiovascular disease was 2.9-fold higher overall; heart failure risk was 5.2-fold higher and ischemic heart disease risk was 2.4-fold higher relative to controls, with higher cumulative incidences at 20 years.\"},{\"question\":\"Which treatment exposures were linked to higher heart failure versus ischemic heart disease risk?\",\"answer\":\"Heart failure risk was associated with anthracycline-containing chemotherapy regimens alone or with combined modality therapy, while higher ischemic heart disease risk was identified only in those treated with radiotherapy.\"}]","Long-term cardiac morbidity in adolescent and young adult survivors of classical Hodgkin lymphoma - the British Columbia experience | PDF",1790191351,28,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a11f5466221bf6d1d345eed52c215e75.webp",983,1309,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/518a082f36e25d879eab061f67553fdd.webp",982,1308,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0e834e8e3cb5887456454fac6c75721e.webp",981,1306,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3f6b6fcb48fbf3cdf48f35dadc9f91d4.webp",980,1305]